{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T17:52:41Z","timestamp":1759341161803},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,12,15]],"date-time":"2011-12-15T00:00:00Z","timestamp":1323907200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s12185-011-0968-7","type":"journal-article","created":{"date-parts":[[2011,12,14]],"date-time":"2011-12-14T05:22:30Z","timestamp":1323840150000},"page":"102-106","source":"Crossref","is-referenced-by-count":17,"title":["Rituximab and intravenous immunoglobulin (IVIG) for the management of acquired factor VIII inhibitor in multiple myeloma: case report and review of literature"],"prefix":"10.1007","volume":"95","author":[{"given":"Jameel","family":"Muzaffar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshmikanth","family":"Katragadda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajjad","family":"Haider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Javed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Anaissie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,12,15]]},"reference":[{"key":"968_CR1","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1365-2516.2005.01136.x","volume":"11","author":"PA Holme","year":"2005","unstructured":"Holme PA, Brosstad F, Tjonnford GE. Acquired hemophilia: management of bleeds and immune therapy to eradicate autoantibodies. Haemophilia. 2005;11:510\u20135.","journal-title":"Haemophilia"},{"key":"968_CR2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/ajh.20830","volume":"82","author":"M Franchini","year":"2007","unstructured":"Franchini M, Lippi G. Acquired von Willebrand syndrome: an update. Am J Hematol. 2007;82:368\u201375.","journal-title":"Am J Hematol"},{"key":"968_CR3","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s12185-009-0363-9","volume":"90","author":"I Sari","year":"2009","unstructured":"Sari I, Erkut MA, Ifran A, et al. Multiple myeloma presenting with acquired factor VIII inhibitor. Int J Hematol. 2009;90:166\u20139.","journal-title":"Int J Hematol"},{"issue":"5","key":"968_CR4","doi-asserted-by":"crossref","first-page":"730","DOI":"10.5858\/2000-124-0730-AHIPWH","volume":"124","author":"S Sallah","year":"2000","unstructured":"Sallah S, Nguyen NP, Abdallah JM, Hanrahan LR. Acquired hemophilia in patients with hematologic malignancies. Arch Pathol Lab Med. 2000;124(5):730\u20134.","journal-title":"Arch Pathol Lab Med"},{"key":"968_CR5","first-page":"350","volume":"21","author":"RB Stricker","year":"1994","unstructured":"Stricker RB, Barlogie B, Kiprov DD. Acquired factor VIII inhibitor associated with chronic Interferon-alpha therapy. J Rheumatol. 1994;21:350\u20132.","journal-title":"J Rheumatol"},{"key":"968_CR6","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1172\/JCI105294","volume":"44","author":"HI Glueck","year":"1965","unstructured":"Glueck HI, Hong R. A circulating anticoagulant in gamma-1A-multiple myeloma: its modification by penicillin. J Clin Invest. 1965;44:1866\u201381.","journal-title":"J Clin Invest"},{"key":"968_CR7","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3324\/haematol.2008.001743","volume":"94","author":"A Huth-Kuhne","year":"2009","unstructured":"Huth-Kuhne A, Baudo F, Collins P, Ingerslev J, et al. International recommendations on the diagnosis and treatment of patients with acquired Hemophilia A. Haematologica. 2009;94:566\u201375.","journal-title":"Haematologica"},{"key":"968_CR8","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1055\/s-0038-1656122","volume":"77","author":"C Negrier","year":"1997","unstructured":"Negrier C, Goudemand J, Sultan Y, et al. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor eight bypassing activity. Thromb Haemost. 1997;77:1113\u20139.","journal-title":"Thromb Haemost"},{"key":"968_CR9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1046\/j.1365-2257.2000.00316.x","volume":"22","author":"TT Yee","year":"2000","unstructured":"Yee TT, Taher A, Pasi KJ, et al. A survey of patients with acquired hemophilia in a hemophilia centre over a 28\u00a0year period. Clin Lab Haematol. 2000;22:275\u20138.","journal-title":"Clin Lab Haematol"},{"key":"968_CR10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2516.2007.01474.x","volume":"13","author":"MJ Sumner","year":"2007","unstructured":"Sumner MJ, Geldziler BD, Pedersen M, Seremetis S. Treatment of acquired hemophilia with recombinant activated FVII: a critical appraisal. Haemophilia. 2007;13:451\u201361.","journal-title":"Haemophilia"},{"key":"968_CR11","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1055\/s-0038-1665434","volume":"78","author":"CR Hay","year":"1997","unstructured":"Hay CR, Negrier C, Ludlum CA. The treatment of bleeding in acquired hemophilia with recombinant factor VIIa: a multicenter study. Thromb Haemost. 1997;78:1463\u20137.","journal-title":"Thromb Haemost"},{"key":"968_CR12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1365-2141.2003.04162.x","volume":"121","author":"J Delgado","year":"2003","unstructured":"Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired hemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003;121:21\u201335.","journal-title":"Br J Haematol"},{"key":"968_CR13","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2006-06-029850","volume":"109","author":"PW Collins","year":"2007","unstructured":"Collins PW, Hirsch S, Baglin TP, Dolan G, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors\u2019 Organisation. Blood. 2007;109:1870\u20137.","journal-title":"Blood"},{"key":"968_CR14","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1365-2516.2004.01031.x","volume":"10","author":"YW Huang","year":"2004","unstructured":"Huang YW, Saidi P, Philipp C. Acquired Factor VIII inhibitors in non-hemophiliac patients: clinical experience of 15 cases. Haemophilia. 2004;10:713\u201321.","journal-title":"Haemophilia"},{"issue":"2","key":"968_CR15","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1046\/j.1365-2516.2001.00489.x","volume":"7","author":"AC Dykes","year":"2001","unstructured":"Dykes AC, walker ID, Lowe GD, Tait RC. Combined prednisolone and intravenous immunoglobulin treatment for acquired factor VIII inhibitors: a 2\u00a0year review. Haemophilia. 2001;7(2):160\u20133.","journal-title":"Haemophilia"},{"issue":"12","key":"968_CR16","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1182\/blood-2003-11-4075","volume":"103","author":"R Stasi","year":"2004","unstructured":"Stasi R, Brunetti M, Stipa E, et al. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood. 2004;103(12):4424\u20138.","journal-title":"Blood"},{"key":"968_CR17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3324\/haematol.10553","volume":"92","author":"WR Sperr","year":"2007","unstructured":"Sperr WR, Lechner K, Pabinger I. Rituximab for the treatment of acquired antibodies to factor VIII. Haematologica. 2007;92:66\u201371.","journal-title":"Haematologica"},{"key":"968_CR18","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/blood.V86.2.797.bloodjournal862797","volume":"86","author":"RS Schwartz","year":"1995","unstructured":"Schwartz RS, Gabriel DA, Aledort LM, Green D, Kessler CM. A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high dose intravenous gammaglobulin. Blood. 1995;86:797\u2013804.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-011-0968-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-011-0968-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-011-0968-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T01:26:00Z","timestamp":1639963560000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-011-0968-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,15]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["968"],"URL":"https:\/\/doi.org\/10.1007\/s12185-011-0968-7","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,15]]}}}